# Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer

> **NCT03786575** · NA · UNKNOWN · sponsor: **Peking Union Medical College** · enrollment: 50 (estimated)

## Conditions studied

- Breast Neoplasm Female
- Therapeutics
- Mutation

## Interventions

- **DIAGNOSTIC_TEST:** Next Generation Sequencing (NGS) detection

## Key facts

- **NCT ID:** NCT03786575
- **Lead sponsor:** Peking Union Medical College
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-01
- **Primary completion:** 2021-02-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03786575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03786575, "Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03786575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*